Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung ...

Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

RIDGEFIELD, Conn., May 22, 2025 /PRNewswire/ --Boehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO ...

Nantes, France, 23 May 2025 – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today proudly announced that its partner Boehringer Ingelheim will present new clinical data from two early ...

Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with ...

The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines) Inc. the prestigious Presidential ...